Advanced search
Start date
Betweenand

Gellan/retrograded starch mucoadhesives systems intended for the colonic release of bevacizumab to cancer treatment.

Grant number: 15/21412-0
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): October 01, 2016
Effective date (End): December 31, 2018
Field of knowledge:Health Sciences - Pharmacy - Pharmaceutical Technology
Principal researcher:Maria Palmira Daflon Gremião
Grantee:Valéria Maria de Oliveira Cardoso
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Colorectal cancer is the third highest incidence among men and women worldwide. Intravenous chemotherapy is the therapeutic alternative most commonly used in the treatment against of the most types of cancers. However, their effectiveness is limited due to lack of specificity/selectivity of chemotherapeutic agents necessitates that makes necessary the high doses administration, leading severe systemic side effects. Bevacizumab was the first monoclonal antibody approved by the FDA for anticancer therapy, and their effectiveness has been demonstrated in the treatment of several solid tumors types. The colon specific release of bevacizumab, by the oral administration of nanostructured systems, represents a promising strategy to increase its specificity action and, subsequent antitumor activity in colon cancer. The bio/mucoadhesive propertie and specific enzymatic degradability of resistant starch and gellan makes them promising materials for the development of colon specific drug release systems. The bevavizumabe delivery for colon in polymeric nanocarriers systems is a rational strategy to increase the biological interaction with the tumoral tissue. Resistant starch and gellan nanoparticles containing bevacizumab will be prepared by polyelectrolytic complexation and characterized by the association efficiency analysis, size, shape, zeta potential, circular dichroism, rheological and thermal properties (DSC and TG/DTG). Cell permeability will be evaluate in Caco-2 cell monolayers. The performance of the nanoparticles as bevacizumab controlled release systems will be evaluated by the vitro release study, in media with pH values that resembles the GIT different portions, and followed by determination of the drug release mechanisms.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
VICTORELLI, FRANCESCA DAMIANI; DE OLIVEIRA CARDOSO, VALERIA MARIA; FERREIRA, NATALIA NORONHA; FIORAMONTI CALIXTO, GIOVANA MARIA; FONTANA, CARLA RAQUEL; BALTAZAR, FATIMA; DAFLON GREMIAO, MARIA PALMIRA; CHORILLI, MARLUS. Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate drug delivery systems for cancer treatment: A review. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, v. 153, p. 273-284, AUG 2020. Web of Science Citations: 0.
DE OLIVEIRA CARDOSO, VALERIA MARIA; DAFLON GREMIAO, MARIA PALMIRA; FERREIRA CURY, BEATRIZ STRINGHETTI. Mucin-polysaccharide interactions: A rheological approach to evaluate the effect of pH on the mucoadhesive properties. International Journal of Biological Macromolecules, v. 149, p. 234-245, APR 15 2020. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.